Observational studyThe journal of headache and pain2025
Circulating CGRP as a diagnostic biomarker in female migraine patients: a single-center case-control study.
Observational study in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Sildenafil provokes headache but not migraine in men with migraine without aura: a randomized, placebo-controlled crossover trial.The journal of headache and pain · 2026Trial
- Trial
- Plasma CGRP Levels in Migraine: A Registry for Migraine Study.Neurology · 2026Observational
- Mechanistic investigation of HMGB1 in an in vitro model of the trigeminovascular system under migraine-like conditions.The journal of headache and pain · 2026Article
- Corneal Nerves Promote Alkali Burn Repair by Modulating Macrophages and Neutrophils via Calcitonin Gene-Related Peptide.Investigative ophthalmology & visual science · 2026Article
- State-dependent facial pulsation asymmetry and phase asynchrony measured by imaging photoplethysmography and their coupling with contingent negative variation in migraine.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine constitutes the predominant cause of disability-adjusted life years (DALYs), yet remains diagnostically challenging due to lack of biomarkers. Calcitonin gene-related peptide (CGRP) has been recognized as the pathophysiological cornerstone of migraine. Despite the therapeutic breakthrough of anti-CGRP therapies, their clinical efficacy remains limited. Given higher prevalence, frequency and severity of migraine in women, this study aims to investigate the diagnostic and therapeutic value of plasma CGRP in female migraine patients.
methodsThis prospective observational study enrolled 184 female migraine patients and 85 healthy controls. CGRP concentrations were quantitatively analyzed using a magnetic particle chemiluminescent immunoassay (MP-CLIA) platform. High- and low-expression subgroups were stratified according to a predefined cutoff value of serum CGRP levels. Additionally, patients who received the CGRP receptor antagonist rimegepant during the acute phase of migraine were analyzed.
resultsCirculating CGRP concentrations were significantly higher in female migraine patients than those in healthy controls. Receiver operating characteristic (ROC) curve analysis determined that 40.00 pg/mL was the optimal cutoff value for subgroup stratification of CGRP levels. Using this threshold, migraine patients were classified into a high-CGRP subgroup (n = 112) and a low-CGRP subgroup (n = 72). A comparative analysis showed that the high-CGRP group had a higher monthly migraine attack frequency (median [interquartile range, IQR]: 4 [2-8] vs. 3 [2-4]; P = 0.013) and a greater prevalence of pericranial tender points (45.5% vs. 29.2%; P = 0.026). Among patients treated with rimegepant, 45.0% achieved pain-free status 2 h after dosing. Multivariate logistic regression identified shorter migraine attack duration as an independent predictor of therapeutic response (OR = 0.96; 95% CI: 0.93-1.00; P = 0.027). Although CGRP concentrations were moderately elevated in the rimegepant responder group, no statistically significant intergroup difference was observed.
conclusionsElevated serum CGRP concentrations exhibited substantial discriminative ability between female migraine patients and healthy controls. Baseline CGRP levels showed some association with rimegepant response, despite no significant statistical difference.
trial registrationChiCTR2500107844 ( www.medicalresearch.org.cn ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.